Fig. 2: Relative expression level of HSPG2 was normalized to β-actin.
From: HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia
a in healthy controls and AML patients by RT-qPCR. b in different stage of AML by RT-qPCR. c in cell lines by RT-qPCR. d Western blot analysis of HSPG2 performed on healthy controls and on AML patients. β-actin was used as a normalizer. AML acute myeloid leukemia, Non-M3 AML non M3 acute myeloid leukemia, CN-AML cytogenetically normal acute myeloid leukemia, CON control. All the data are presented as the means ± SDs and analyzed by GraphPad Prism 5.01, *P < 0.05, **P < 0.01, and ***P < 0.001.
